Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Acurx Pharmaceuticals, Inc. New York

First ever head-to-head comparison of gut microbiome changes associated with ibezapolstat (IBZ) to other anti-CDI antibiotics in a germ-free mouse modelChanges in alpha and beta microbiome diversities following IBZ treatment were less pronounced compared to those observed in vancomycin (VAN)-or metronidazole (MET)-treated groups, complementing prior Phase 2 clinical findings showing IBZ's more selective antibacterial activityNotable differences were observed between the microbiome of IBZ- and fidaxomicin (FDX)-treated groups, which may allow for differentiation of these two anti-CDI antibiotics in future studiesResults establish IBZ differentiating effects on the gut microbiome, indicating a more selective spectrum of microbiome alteration compared to broader-spectrum antibiotics like VAN and MET and a narrower spectrum of microbiome alteration compared to FDXPreparation continues to advance IBZ into international Ph3 clinical trials for treatment of CDIIBZ has previously been granted FDA QIDP and Fast-Track Designation and has received SME (Small and Medium-sized Enterprise) designation by the EMA View original content:https://www.prnewswire.co.uk/news-releases/acurx-announces-publication-of-nonclinical-in-vivo-data-differentiating-ibezapolstats-gut-microbiome-effects-from-other-anti-cdi-antibiotics-302386466.html